# Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

> **NCT00810017** · PHASE2 · TERMINATED · sponsor: **Medstar Health Research Institute** · enrollment: 2 (actual)

## Conditions studied

- HER-2 Positive Metastatic Breast Cancer

## Interventions

- **DRUG:** Etoposide
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00810017
- **Lead sponsor:** Medstar Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Terminated due to difficulty in accruing patients
- **Last updated:** 2022-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00810017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00810017, "Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00810017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*